ОЦЕНКА ЭФФЕКТИВНОСТИ КОРРЕКЦИИ ГИПЕРГОМОЦИСТЕИНЕМИИ С ПОЗИЦИЙ ДОКАЗАТЕЛЬНОЙ МЕДИЦИНЫ
Аннотация
В данной работе проведен анализ литературных данных научной литературы и MEDLINE, касающихся проблемы гипергомоцистеинемии, как дополнительного модифицируемого фактора риска сердечно-сосудистых заболеваний, способов его коррекции и оценки эффективности полученных результатов.
Литература
Результаты пилотного исследования SEARCH–Pilot Study / А.В. Сусеков [и др.] // Клиническая фармакология и терапия. — 2001. — № 10. — С. 69–74.
A quantitative assessment of plasma homocysteine as a risk factor for vascular disease / C. Boushey [et al.] // JAMA. — 1995. — Vol. 274. — P. 1049–1057.
Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial / F. Baker [et al.] // Circulation. — 2002. — Vol. 106, № 2. — P. 741.
Cystathionine B–synthase mutations in homocystinuria / J.P. Kraus [et al.] // Hum. Mutat. — 1999. — № 13. — P. 362–375.
Decreased rate of coronary restenosis after lowering of plasma homocysteine levels / G. Schnyder [et al.] // N. Engl. J. Med. — 2001. — Vol. 345. — P. 1593–1600.
Folate therapy and in stent restenosis after coronary stenting / H. Lange [et al.] // N. Engl. J. Med. — 2004. — Vol. 26. — P. 2673–2681.
Folic acid and vitamin E supplementation effects on homocysteinemia, endothelial function and plasma anti–oxidant capacity in young myocardial infarction patients / D. Assanelli [et al.] // Pharmacol. Res. — 2004. — Vol. 49. — P. 79–84.
Folic acid supplementation for 3 weeks reduces pulse pressure and large artery stiffness independent of MTHFR phenotype / C. Williams [et al.] // Am. J. Clin. Nutr. — 2005. — Vol. 82. — P. 26–31.
Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence / D. Wald [et al.] // BMJ. — 2006. — Vol. 333. — P. 1114–1117.
Homocysteine and cardiovascular disease: evidence on causality from a meta–analysis / D.S. Wald [et al.] // BMJ. — 2002. — Vol. 325. — P. 1202–1206.
Homocysteine and ischemic heart disease / N. Wald [et al.] // Arch. Intern. Med. — 1998. — Vol. 1158. — P. 862–867.
Homocysteine and risk of ischemic heart disease and stroke: a meta–analysis / Homocysteine Studies Collaboration // JAMA. 2002. — Vol. 288. — P. 2015–2022.
Homocysteine and stroke: evidence on a causal link from mendelian randomisation / J. P. Cases [et al.] // Lancet. — 2005. — Vol.365. — P.224–232.
Homocysteine lowering and cardiovascular events after acute myocardial infarction / K. H. Bonaa [et al.] // N. Engl. J. Med. — 2006. — Vol. 354. — P. 1578–1588.
Homocysteine lowering with folic acid and B vitamins in vascular disease. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators / E. Lonn [et al.] // N. Engl. J. Med. — 2006. — Vol. 354. — P. 1567–1577.
Lentz, S. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine / S. Lentz, J. Sadler // J. Clin. Invest. — 1991. — Vol. 88. — P. 1906–1914.
Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial / J.F. Toole [et al.] // JAMA. — 2005. — Vol. 5. — P. 565–575.
Meta–analysis of MTHFR 677C®T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? / S.J. Lewis [et al.] // BMJ. — 2005. — Vol. 331. — P. 1053.
Plasma homocysteine and severity of atherosclerosis in young adults with lower limb atherosclerotic disease / M.L. Van der Berg [et al.] // Arterioscler. Thromb. Vasc. Biol. — 1996. — № 16. — P. 165–175.
Plasma homocysteine concentration is decreased by dietary intervention / M. Silaste [et al.] // Br. J. Nutr. — 2003. — Vol. 89. — P. 295–301.
Plasma total homocysteine and memory in the elderly: the Hordaland Homocysteine Study / E. Nurk [et al.] // Ann. Neurol. — 2005. — № 6. — P. 847–857.
Proceedings of American Heart Association 2006 Scientific Sessions [Electronic resource] / Ed. С. Albert. — Chicago, IL. — 2006. — Mode of access : http://www.americanheart.org/presenter.jhtml?identifier=3043436 — Date of access: 20.01.2008
Recent data are not in conflict with homocysteine as a cardiovascular risk factor / H. Refsum [et al.] // Curr. Opin. Lipidol. — 1998. — Vol. 6, №9. — P. 533–539.
Secondary prevention with folic acid: results of the Goes extension study / A. Liem [et al.] // Heart. — 2005. — Vol. 91. — P. 1213–1214.
Treatment of hyperhomocysteinemia with folic acid and vitamin B12 and B6 attenuates thrombin generation / A. Undas [et al.] // Thromb. Res. — 1999. — Vol. 95. — P. 281–288.
Yap, S. Homocysteinemia due to cystathionine–в–synthase deficiency in Ireland: 25 years experience of newborn screened and treated population with reference to a clinical outcome and biochemical control / S. Yap, E. Naughten // J. Inherit. Metab. Dis. — 1998. — № 21. — P. 738–747.
